Donald N Forthal

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(949) 824-3366
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    The Fc neonatal receptor and antibody-dependent enhancement of dengue virus infection
    NIH R21AI149255Jan 23, 2020 - Dec 31, 2021
    Role: Principal Investigator
    The role of antibody and the Fc neonatal receptor in transmitted/founder strain selection
    NIH R01AI118581Jun 15, 2015 - May 31, 2021
    Role: Principal Investigator
    The impact of antibody and pH on female-to-male SIV infection
    NIH R01AI102715Jul 6, 2012 - Jun 30, 2017
    Role: Principal Investigator
    Broadly Reactive Antibodies Against Chimeric Virus-Host Antigens
    NIH R01AI090656Jun 14, 2010 - May 31, 2014
    Role: Principal Investigator
    Iron Starvation: A novel strategy for HIV and Chlamydia microbicides
    NIH R33AI079775May 1, 2009 - Jul 31, 2016
    Role: Co-Principal Investigator
    Iron Starvation: A novel strategy for HIV and Chlamydia microbicides
    NIH R21AI079775May 1, 2009 - Aug 15, 2011
    Role: Principal Investigator
    Protective immunity against HIV: the role of IgG subclass and glycosylation
    NIH R21AI078477Mar 1, 2008 - Feb 28, 2011
    Role: Principal Investigator
    Fcy Receptor Polymorphisms and Risk of HIV Infection
    NIH R21AI073147Jul 15, 2007 - Jun 30, 2009
    Role: Principal Investigator
    Novel Biological Activities of Anti-Viral Antibody
    NIH R01AI052039Jun 1, 2002 - May 31, 2007
    Role: Principal Investigator
    IMMUNOPROPHYLAXIS--DEFINING PROTECTIVE ANTIBODY FUNCTION
    NIH R03AI044610Jun 1, 1999 - May 31, 2002
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Impact of HLA allele-KIR partners on sexually transmitted HIV-1 infection. J Infect Dis. 2024 Aug 29. Serrano-Rísquez C, Omar M, Rallón N, Benito JM, Gómez-Vidal A, Márquez FJ, Alján M, Rivero-Juárez A, Pérez-Valero I, Rivero A, Sinangil F, Saulle I, Biasin M, Clerici M, Forthal D, Saéz ME, Caruz A. PMID: 39208444.
      View in: PubMed   Mentions:    Fields:    
    2. SARS-CoV-2 infection of endothelial cells, dependent on flow-induced ACE2 expression, drives hypercytokinemia in a vascularized microphysiological system. Front Cardiovasc Med. 2024; 11:1360364. Hatch CJ, Piombo SD, Fang JS, Gach JS, Ewald ML, Van Trigt WK, Coon BG, Tong JM, Forthal DN, Hughes CCW. PMID: 38576426; PMCID: PMC10991679.
      View in: PubMed   Mentions: 3  
    3. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial. JCI Insight. 2024 Mar 14; 9(8). Park HS, Yin A, Barranta C, Lee JS, Caputo CA, Sachithanandham J, Li M, Yoon S, Sitaras I, Jedlicka A, Eby Y, Ram M, Fernandez RE, Baker OR, Shenoy AG, Mosnaim GS, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Lau B, Ehrhardt S, Baksh SN, Shapiro JR, Ou J, Na YB, Knoll MD, Ornelas-Gatdula E, Arroyo-Curras N, Gniadek TJ, Caturegli P, Wu J, Ndahiro N, Betenbaugh MJ, Ziman A, Hanley DF, Casadevall A, Shoham S, Bloch EM, Gebo KA, Tobian AA, Laeyendecker O, Pekosz A, Klein SL, Sullivan DJ. PMID: 38483534; PMCID: PMC11141865.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    4. A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Model. bioRxiv. 2024 Feb 15. Prakash S, Dhanushkodi NR, Singer M, Quadiri A, Zayou L, Vahed H, Coulon PG, Ibraim IC, Tafoya C, Hitchcock L, Landucci G, Forthal DN, El Babsiri A, Tifrea DF, Figueroa CJ, Nesburn AB, Kuppermann BD, Gil D, Jones TM, Ulmer JB, BenMohamed L. PMID: 38405942; PMCID: PMC10888826.
      View in: PubMed   Mentions:
    5. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial. medRxiv. 2023 Dec 15. Park HS, Yin A, Barranta C, Lee JS, Caputo CA, Sachithanandham J, Li M, Yoon S, Sitaras I, Jedlicka A, Eby Y, Ram M, Fernandez RE, Baker OR, Shenoy AG, Mosnaim GS, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Lau B, Ehrhardt S, Baksh SN, Shapiro JR, Ou J, Na YB, Knoll MD, Ornelas-Gatdula E, Arroyo-Curras N, Gniadek TJ, Caturegli P, Wu J, Ndahiro N, Betenbaugh MJ, Ziman A, Hanley DF, Casadevall A, Shoham S, Bloch EM, Gebo KA, Tobian AAR, Laeyendecker O, Pekosz A, Klein SL, Sullivan DJ. PMID: 37131659; PMCID: PMC10153328.
      View in: PubMed   Mentions:
    6. Erratum for Gebo et al., "Early antibody treatment, inflammation, and risk of post-COVID conditions". mBio. 2024 Jan 16; 15(1):e0297923. Gebo KA, Heath SL, Fukuta Y, Zhu X, Baksh S, Abraham AG, Habtehyimer F, Shade D, Ruff J, Ram M, Laeyendecker O, Fernandez RE, Patel EU, Baker OR, Shoham S, Cachay ER, Currier JS, Gerber JM, Meisenberg B, Forthal DN, Hammitt LL, Huaman MA, Levine A, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Anjan S, Gniadek T, Kassaye S, Blair JE, Lane K, McBee NA, Gawad AL, Das P, Klein SL, Pekosz A, Bloch EM, Hanley D, Casadevall A, Tobian AAR, Sullivan DJ, CSSC-004 Consortium. PMID: 38095433; PMCID: PMC10790766.
      View in: PubMed   Mentions: 1     Fields:    
    7. COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial. Microbiol Spectr. 2024 Jan 11; 12(1):e0328623. Habtehyimer F, Zhu X, Redd AD, Gebo KA, Abraham AG, Patel EU, Laeyendecker O, Gniadek TJ, Fernandez RE, Baker OR, Ram M, Cachay ER, Currier JS, Fukuta Y, Gerber JM, Heath SL, Meisenberg B, Huaman MA, Levine AC, Shenoy A, Anjan S, Blair JE, Cruser D, Forthal DN, Hammitt LL, Kassaye S, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Abinante M, Oei KS, Cluzet V, Cordisco ME, Greenblatt B, Rausch W, Shade D, Gawad AL, Klein SL, Pekosz A, Shoham S, Casadevall A, Bloch EM, Hanley D, Tobian AAR, Sullivan DJ. PMID: 38009954; PMCID: PMC10783116.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    8. Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology. Nat Commun. 2023 11 03; 14(1):7062. Streblow DN, Hirsch AJ, Stanton JJ, Lewis AD, Colgin L, Hessell AJ, Kreklywich CN, Smith JL, Sutton WF, Chauvin D, Woo J, Bimber BN, LeBlanc CN, Acharya SN, O'Roak BJ, Sardar H, Sajadi MM, Tehrani ZR, Walter MR, Martinez-Sobrido L, Kobie JJ, Reader RJ, Olstad KJ, Hobbs TR, Saphire EO, Schendel SL, Carnahan RH, Knoch J, Branco LM, Crowe JE, Van Rompay KKA, Lovalenti P, Forthal DN, Haigwood NL. PMID: 37923717; PMCID: PMC10624670.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    9. Early antibody treatment, inflammation, and risk of post-COVID conditions. mBio. 2023 Oct 31; 14(5):e0061823. Gebo KA, Heath SL, Fukuta Y, Zhu X, Baksh S, Abraham AG, Habtehyimer F, Shade D, Ruff J, Ram M, Laeyendecker O, Fernandez RE, Patel EU, Baker OR, Shoham S, Cachay ER, Currier JS, Gerber JM, Meisenberg B, Forthal DN, Hammitt LL, Huaman MA, Levine A, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Anjan S, Gniadek T, Kassaye S, Blair JE, Lane K, McBee NA, Gawad AL, Das P, Klein SL, Pekosz A, Bloch EM, Hanley D, Casadevall A, Tobian AAR, Sullivan DJ, CSSC-004 Consortium. PMID: 37724870; PMCID: PMC10653913.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    10. Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study. Lancet Microbe. 2023 09; 4(9):e692-e703. Zhu X, Gebo KA, Abraham AG, Habtehyimer F, Patel EU, Laeyendecker O, Gniadek TJ, Fernandez RE, Baker OR, Ram M, Cachay ER, Currier JS, Fukuta Y, Gerber JM, Heath SL, Meisenberg B, Huaman MA, Levine AC, Shenoy A, Anjan S, Blair JE, Cruser D, Forthal DN, Hammitt LL, Kassaye S, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Abinante M, Broderick P, Cluzet V, Cordisco ME, Greenblatt B, Petrini J, Rausch W, Shade D, Lane K, Gawad AL, Klein SL, Pekosz A, Shoham S, Casadevall A, Bloch EM, Hanley D, Sullivan DJ, Tobian AAR. PMID: 37659419; PMCID: PMC10475695.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    11. Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials. Transfusion. 2023 09; 63(9):1639-1648. Huaman MA, Raval JS, Paxton JH, Mosnaim GS, Patel B, Anjan S, Meisenberg BR, Levine AC, Marshall CE, Yarava A, Shenoy AG, Heath SL, Currier JS, Fukuta Y, Blair JE, Spivak ES, Petrini JR, Broderick PB, Rausch W, Cordisco M, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Kassaye SG, Ram M, Wang Y, Das P, Lane K, McBee NA, Gawad AL, Karlen N, Ford DE, Laeyendecker O, Pekosz A, Klein SL, Ehrhardt S, Lau B, Baksh SN, Shade DM, Casadevall A, Hanley DF, Ou J, Gniadek TJ, Ziman A, Shoham S, Gebo KA, Bloch EM, Tobian AAR, Sullivan DJ, Gerber JM. PMID: 37534607; PMCID: PMC10720768.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    12. Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial. J Infect Dis. 2023 05 29; 227(11):1266-1273. Baksh SN, Heath SL, Fukuta Y, Shade D, Meisenberg B, Bloch EM, Tobian AAR, Spivak ES, Patel B, Gerber J, Raval JS, Forthal D, Paxton J, Mosnaim G, Anjan S, Blair J, Cachay E, Currier J, Das P, Huaman M, Sutcliffe C, Yarava A, Casadevall A, Sullivan D, Hanley D, Gebo KA. PMID: 36722044; PMCID: PMC10226658.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    13. Comment on the immunogenicity of the Noora vaccine against SARS-CoV-2. J Med Virol. 2023 05; 95(5):e28731. Forthal DN. PMID: 37212298; PMCID: PMC10618008.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    14. Vaccination against SARS-CoV-2 using extracellular blebs derived from spike protein-expressing dendritic cells. Cell Immunol. 2023 04; 386:104691. Young Chung J, Thone MN, Davies JE, Gach JS, Huw Davies D, Forthal DN, Kwon YJ. PMID: 36822152; PMCID: PMC9933546.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsPHPublic Health
    15. Early Treatment, Inflammation and Post-COVID Conditions. medRxiv. 2023 Feb 16. Gebo KA, Heath SL, Fukuta Y, Zhu X, Baksh S, Abraham AG, Habtehyimer F, Shade D, Ruff J, Ram M, Laeyendecker O, Fernandez RE, Patel EU, Baker OR, Shoham S, Cachay ER, Currier JS, Gerber JM, Meisenberg B, Forthal DN, Hammitt LL, Huaman MA, Levine A, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Anjan S, Gniadek T, Kassaye S, Blair JE, Lane K, McBee NA, Gawad AL, Das P, Klein SL, Pekosz A, Casadevall A, Bloch EM, Hanley D, Tobian AAR, Sullivan DJ. PMID: 36824860; PMCID: PMC9949202.
      View in: PubMed   Mentions:
    16. Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. Clin Infect Dis. 2023 02 08; 76(3):e477-e486. Shoham S, Bloch EM, Casadevall A, Hanley D, Lau B, Gebo K, Cachay E, Kassaye SG, Paxton JH, Gerber J, Levine AC, Naeim A, Currier J, Patel B, Allen ES, Anjan S, Appel L, Baksh S, Blair PW, Bowen A, Broderick P, Caputo CA, Cluzet V, Cordisco ME, Cruser D, Ehrhardt S, Forthal D, Fukuta Y, Gawad AL, Gniadek T, Hammel J, Huaman MA, Jabs DA, Jedlicka A, Karlen N, Klein S, Laeyendecker O, Lane K, McBee N, Meisenberg B, Merlo C, Mosnaim G, Park HS, Pekosz A, Petrini J, Rausch W, Shade DM, Shapiro JR, Singleton JR, Sutcliffe C, Thomas DL, Yarava A, Zand M, Zenilman JM, Tobian AAR, Sullivan DJ. PMID: 35579509; PMCID: PMC9129191.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    17. IFNL4 genotype influences the rate of HIV-1 seroconversion in men who have sex with men. Virulence. 2022 12; 13(1):757-763. Meza G, Galián F, Jaimes-Bernal C, Márquez FJ, Sinangil F, Scagnolari C, Real LM, Forthal D, Caruz A. PMID: 35481423; PMCID: PMC9067526.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    18. No association of a risk variant for severe COVID-19 with HIV protection in three cohorts of highly exposed individuals. PNAS Nexus. 2022 Jul; 1(3):pgac138. Sironi M, Cagliani R, Biasin M, Lo Caputo S, Saulle I, Forni D, Real LM, Pineda JA, Exposito A, Saez ME, Sinangil F, Forthal D, Caruz A, Clerici M. PMID: 36741450; PMCID: PMC9896871.
      View in: PubMed   Mentions: 1  
    19. Correction to: Prevention and Treatment of Monkeypox. Drugs. 2022 Aug; 82(12):1343. Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. PMID: 35994201; PMCID: PMC9629312.
      View in: PubMed   Mentions: 1     Fields:    
    20. Prevention and Treatment of Monkeypox. Drugs. 2022 Jun; 82(9):957-963. Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. PMID: 35763248; PMCID: PMC9244487.
      View in: PubMed   Mentions: 165     Fields:    Translation:HumansAnimalsCells
    21. Association between vaccine preventable diseases in children and improved sanitation following a nationwide sanitation campaign in India: an ecological analysis. BMJ Open. 2022 04 20; 12(4):e052937. Singh P, Forthal DN, Shah M, Bruckner TA. PMID: 35443943; PMCID: PMC9021782.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    22. How do I implement an outpatient program for the administration of convalescent plasma for COVID-19? Transfusion. 2022 05; 62(5):933-941. Bloch EM, Tobian AAR, Shoham S, Hanley DF, Gniadek TJ, Cachay ER, Meisenberg BR, Kafka K, Marshall C, Heath SL, Shenoy A, Paxton JH, Levine A, Forthal D, Fukuta Y, Huaman MA, Ziman A, Adamski J, Gerber J, Cruser D, Kassaye SG, Mosnaim GS, Patel B, Metcalf RA, Anjan S, Reisler RB, Yarava A, Lane K, McBee N, Gawad A, Raval JS, Zand M, Abinante M, Broderick PB, Casadevall A, Sullivan D, Gebo KA. PMID: 35352362; PMCID: PMC9086144.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsPHPublic Health
    23. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. N Engl J Med. 2022 05 05; 386(18):1700-1711. Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley DF. PMID: 35353960; PMCID: PMC9006786.
      View in: PubMed   Mentions: 135     Fields:    Translation:Humans
    24. Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv. 2021 Dec 21. Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley DF. PMID: 34981068; PMCID: PMC8722611.
      View in: PubMed   Mentions: 2  
    25. Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection. medRxiv. 2021 Dec 14. Shoham S, Bloch EM, Casadevall A, Hanley D, Lau B, Gebo K, Cachay E, Kassaye SG, Paxton JH, Gerber J, Levine AC, Currier J, Patel B, Allen ES, Anjan S, Appel L, Baksh S, Blair PW, Bowen A, Broderick P, Caputo CA, Cluzet V, Cordisco ME, Cruser D, Ehrhardt S, Forthal D, Fukuta Y, Gawad AL, Gniadek T, Hammel J, Huaman MA, Jabs DA, Jedlicka A, Karlen N, Klein S, Laeyendecker O, Lane K, McBee N, Meisenberg B, Merlo C, Mosnaim G, Park HS, Pekosz A, Petrini J, Rausch W, Shade DM, Shapiro JR, Singleton JR, Sutcliffe C, Thomas DL, Yarava A, Zand M, Zenilman JM, Tobian AAR, Sullivan D. PMID: 34931202; PMCID: PMC8687473.
      View in: PubMed   Mentions:
    26. Infection prevention strategies are highly protective in COVID-19 units while main risks to healthcare professionals come from coworkers and the community. Antimicrob Resist Infect Control. 2021 11 22; 10(1):163. Gohil SK, Quan KA, Madey KM, King-Adelsohn S, Tjoa T, Tifrea D, Crews BO, Monuki ES, Khan S, Schubl SD, Bittencourt CE, Detweiler N, Chang W, Willis L, Khusbu U, Saturno A, Rezk SA, Figueroa C, Jain A, Assis R, Felgner P, Edwards R, Hsieh L, Forthal D, Wilson WC, Stamos MJ, Huang SS. PMID: 34809702; PMCID: PMC8608236.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    27. CD46 Genetic Variability and HIV-1 Infection Susceptibility. Cells. 2021 11 09; 10(11). Serrano-Rísquez C, Omar M, Gómez-Vidal MA, Real LM, Pineda JA, Rivero A, Rivero-Juárez A, Forthal D, Márquez FJ, Lo Caputo S, Clerici M, Biasin M, Caruz A. PMID: 34831317; PMCID: PMC8622916.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. Internalization of HIV-1 by Phagocytes Is Increased When Virions Are Opsonized with Multimeric Antibody in the Presence of Complement. J Virol. 2022 01 26; 96(2):e0168921. Gach JS, Matsuno SY, Mercado M, Hangartner L, Forthal DN. PMID: 34730392; PMCID: PMC8791273.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    29. Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. Retrovirology. 2021 10 30; 18(1):35. Cheng HD, Dowell KG, Bailey-Kellogg C, Goods BA, Love JC, Ferrari G, Alter G, Gach J, Forthal DN, Lewis GK, Greene K, Gao H, Montefiori DC, Ackerman ME. PMID: 34717659; PMCID: PMC8557579.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    30. Adaptive immune responses to SARS-CoV-2. Adv Drug Deliv Rev. 2021 05; 172:1-8. Forthal D. PMID: 33610693; PMCID: PMC7891074.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    31. Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone. J Immunol. 2021 03 15; 206(6):1266-1283. Hessell AJ, Li L, Malherbe DC, Barnette P, Pandey S, Sutton W, Spencer D, Wang XH, Gach JS, Hunegnaw R, Tuen M, Jiang X, Luo CC, LaBranche CC, Shao Y, Montefiori DC, Forthal DN, Duerr R, Robert-Guroff M, Haigwood NL, Gorny MK. PMID: 33536254; PMCID: PMC7946713.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    32. COVID-19: An unprecedented challenge and an opportunity for change. Adv Drug Deliv Rev. 2021 04; 171:48-49. Kwon YJ, Forthal D. PMID: 33524417; PMCID: PMC7845530.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    33. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. Drug Discov Today. 2021 02; 26(2):593-603. Rizk JG, Forthal DN, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Pfeiffer JP, Lewin JC. PMID: 33253920; PMCID: PMC7694556.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    34. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020 Sep; 80(13):1267-1292. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. PMID: 32696108; PMCID: PMC7372203.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansCellsPHPublic Health
    35. Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy I COVID-19". Drugs. 2020 09; 80(14):1501-1503. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. PMID: 32880806; PMCID: PMC7471515.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsPHPublic Health
    36. Reopening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-Coronavirus 2019 Expectations, and Creative Solutions. J Pediatr. 2020 08; 223:183-185. Cooper DM, Guay-Woodford L, Blazar BR, Bowman S, Byington CL, Dome J, Forthal D, Konstan MW, Kuppermann N, Liem RI, Ochoa ER, Pollock BH, Price OA, Ramsey BW, Ross LF, Sokol RJ, Wright RJ. PMID: 32445649; PMCID: PMC7239776.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsPHPublic Health
    37. Impact of Th1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. J Virol. 2020 02 28; 94(6). Verma A, Schmidt BA, Elizaldi SR, Nguyen NK, Walter KA, Beck Z, Trinh HV, Dinasarapu AR, Lakshmanappa YS, Rane NN, Matyas GR, Rao M, Shen X, Tomaras GD, LaBranche CC, Reimann KA, Foehl DH, Gach JS, Forthal DN, Kozlowski PA, Amara RR, Iyer SS. PMID: 31827000; PMCID: PMC7158739.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    38. Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. J Virol. 2020 02 28; 94(6). Silva de Castro I, Gordon SN, Liu J, Bissa M, McKinnon K, Trinh HV, Doster MN, Schifanella L, Liyanage NP, Cao J, Cheng O, Foulds K, Roederer M, Koup RA, Shen X, Tomaras GD, Venzon DJ, Forthal DN, Fouts T, Montefiori DC, Tartaglia J, Rao M, Ostrowski M, Franchini G, Vaccari M. PMID: 31896599; PMCID: PMC7158742.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    39. Association of complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine. AIDS. 2020 01 01; 34(1):25-32. Meza G, Expósito A, Royo JL, Ruiz-García C, Sánchez-Arcas B, Marquez FJ, Gómez-Vidal MA, Omar M, Sinangil F, Higgins K, Forthal D, Real LM, Caruz A. PMID: 31634193.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    40. Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC". J Virol. 2019 Nov 01; 93(21). Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL. PMID: 31615930; PMCID: PMC6803259.
      View in: PubMed   Mentions:    Fields:    
    41. Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. J Virol. 2019 10 15; 93(20). Gach JS, Mara KJV, LaBranche CC, van Gils MJ, McCoy LE, Klasse PJ, Montefiori DC, Sanders RW, Moore JP, Forthal DN. PMID: 31375582; PMCID: PMC6798112.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCellsPHPublic Health
    42. Brucellosis Presenting as Cholecystitis: A Case Report and Literature Review. Open Forum Infect Dis. 2019 Oct; 6(10):ofz334. Speiser L, Hsieh L, Huang SS, Bittencourt C, Forthal D. PMID: 31660329; PMCID: PMC6765347.
      View in: PubMed   Mentions: 1  
    43. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. J Virol. 2019 02 01; 93(3). Asbach B, Kibler KV, Köstler J, Perdiguero B, Yates NL, Stanfield-Oakley S, Tomaras GD, Kao SF, Foulds KE, Roederer M, Seaman MS, Montefiori DC, Parks R, Ferrari G, Forthal DN, Phogat S, Tartaglia J, Barnett SW, Self SG, Gottardo R, Cristillo AD, Weiss DE, Galmin L, Ding S, Heeney JL, Esteban M, Jacobs BL, Pantaleo G, Wagner R. PMID: 30429343; PMCID: PMC6340047.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    44. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. J Virol. 2019 02 01; 93(3). Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL. PMID: 30429340; PMCID: PMC6340019.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    45. Blocking HIV-1 replication: are Fc-Fcγ receptor interactions required? J Clin Invest. 2019 01 02; 129(1):53-54. Forthal D, Finzi A. PMID: 30475231; PMCID: PMC6307933.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    46. Antibody-dependent cellular cytotoxicity in HIV infection. AIDS. 2018 11 13; 32(17):2439-2451. Forthal DN, Finzi A. PMID: 30234611; PMCID: PMC6497078.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    47. HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. Nat Med. 2018 06; 24(6):847-856. Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, Silva de Castro I, Doster MN, Galli V, Omsland M, Fujikawa D, Gorini G, Liyanage NPM, Trinh HV, McKinnon KM, Foulds KE, Keele BF, Roederer M, Koup RA, Shen X, Tomaras GD, Wong MP, Munoz KJ, Gach JS, Forthal DN, Montefiori DC, Venzon DJ, Felber BK, Rosati M, Pavlakis GN, Rao M, Sekaly RP, Franchini G. PMID: 29785023; PMCID: PMC5992093.
      View in: PubMed   Mentions: 45     Fields:    Translation:AnimalsCells
    48. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. J Virol. 2018 01 15; 92(2). Malherbe DC, Mendy J, Vang L, Barnette PT, Reed J, Lakhashe SK, Owuor J, Gach JS, Legasse AW, Axthelm MK, LaBranche CC, Montefiori D, Forthal DN, Park B, Wilson JM, McLinden JH, Xiang J, Stapleton JT, Sacha JB, Haynes BF, Liao HX, Ruprecht RM, Smith J, Gurwith M, Haigwood NL, Alexander J. PMID: 29093095; PMCID: PMC5752948.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    49. Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. PLoS Pathog. 2017 12; 13(12):e1006793. Gach JS, Bouzin M, Wong MP, Chromikova V, Gorlani A, Yu KT, Sharma B, Gratton E, Forthal DN. PMID: 29281723; PMCID: PMC5760106.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    50. Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. J Immunol. 2016 12 15; 197(12):4603-4612. Huang Y, Ferrari G, Alter G, Forthal DN, Kappes JC, Lewis GK, Love JC, Borate B, Harris L, Greene K, Gao H, Phan TB, Landucci G, Goods BA, Dowell KG, Cheng HD, Bailey-Kellogg C, Montefiori DC, Ackerman ME. PMID: 27913647; PMCID: PMC5137799.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsPHPublic Health
    51. Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016 10 06; 22(10):1192. Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, Rao M, Chung AW, Dowell KG, Bailey-Kellogg C, Brown EP, Ackerman ME, Vargas-Inchaustegui DA, Whitney S, Doster MN, Binello N, Pegu P, Montefiori DC, Foulds K, Quinn DS, Donaldson M, Liang F, Loré K, Roederer M, Koup RA, McDermott A, Ma ZM, Miller CJ, Phan TB, Forthal DN, Blackburn M, Caccuri F, Bissa M, Ferrari G, Kalyanaraman V, Ferrari MG, Thompson D, Robert-Guroff M, Ratto-Kim S, Kim JH, Michael NL, Phogat S, Barnett SW, Tartaglia J, Venzon D, Stablein DM, Alter G, Sekaly RP, Franchini G. PMID: 27711066.
      View in: PubMed   Mentions: 10     Fields:    
    52. Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251. J Virol. 2016 10 01; 90(19):8487-95. Gach JS, Venzon D, Vaccari M, Keele BF, Franchini G, Forthal DN. PMID: 27440881; PMCID: PMC5021405.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    53. Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. J Immunol. 2016 10 01; 197(7):2726-37. Gordon SN, Liyanage NP, Doster MN, Vaccari M, Vargas-Inchaustegui DA, Pegu P, Schifanella L, Shen X, Tomaras GD, Rao M, Billings EA, Schwartz J, Prado I, Bobb K, Zhang W, Montefiori DC, Foulds KE, Ferrari G, Robert-Guroff M, Roederer M, Phan TB, Forthal DN, Stablein DM, Phogat S, Venzon DJ, Fouts T, Franchini G. PMID: 27591322; PMCID: PMC5026031.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    54. HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. PLoS One. 2016; 11(8):e0160341. Gach JS, Gorlani A, Dotsey EY, Becerra JC, Anderson CT, Berzins B, Felgner PL, Forthal DN, Deeks SG, Wilkin TJ, Casazza JP, Koup RA, Katlama C, Autran B, Murphy RL, Achenbach CJ. PMID: 27500639; PMCID: PMC4976892.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    55. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016 07; 22(7):762-70. Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, Rao M, Chung AW, Dowell KG, Bailey-Kellogg C, Brown EP, Ackerman ME, Vargas-Inchaustegui DA, Whitney S, Doster MN, Binello N, Pegu P, Montefiori DC, Foulds K, Quinn DS, Donaldson M, Liang F, Loré K, Roederer M, Koup RA, McDermott A, Ma ZM, Miller CJ, Phan TB, Forthal DN, Blackburn M, Caccuri F, Bissa M, Ferrari G, Kalyanaraman V, Ferrari MG, Thompson D, Robert-Guroff M, Ratto-Kim S, Kim JH, Michael NL, Phogat S, Barnett SW, Tartaglia J, Venzon D, Stablein DM, Alter G, Sekaly RP, Franchini G. PMID: 27239761; PMCID: PMC5916782.
      View in: PubMed   Mentions: 140     Fields:    Translation:AnimalsCells
    56. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J Virol. 2016 Apr; 90(8):4133-4149. Asbach B, Kliche A, Köstler J, Perdiguero B, Esteban M, Jacobs BL, Montefiori DC, LaBranche CC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Landucci G, Forthal DN, Seaman MS, Hawkins N, Self SG, Sato A, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Francis J, Galmin L, Ding S, Heeney JL, Pantaleo G, Wagner R. PMID: 26865719; PMCID: PMC4810551.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCellsPHPublic Health
    57. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations. Mol Immunol. 2016 Feb; 70:94-103. Hicar MD, Chen X, Kalams SA, Sojar H, Landucci G, Forthal DN, Spearman P, Crowe JE. PMID: 26748387; PMCID: PMC4762738.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    58. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans. EBioMedicine. 2015 Oct; 2(10):1464-77. Williams KL, Cortez V, Dingens AS, Gach JS, Rainwater S, Weis JF, Chen X, Spearman P, Forthal DN, Overbaugh J. PMID: 26629541; PMCID: PMC4634620.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    59. Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants. Proc Natl Acad Sci U S A. 2015 Oct 13; 112(41):12675-80. Loos A, Gach JS, Hackl T, Maresch D, Henkel T, Porodko A, Bui-Minh D, Sommeregger W, Wozniak-Knopp G, Forthal DN, Altmann F, Steinkellner H, Mach L. PMID: 26417081; PMCID: PMC4611627.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    60. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog. 2015 Aug; 11(8):e1005042. Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, Shen X, Duffy R, Xia SM, Schutte RJ, Pemble Iv CW, Dennison SM, Li H, Chao A, Vidnovic K, Evans A, Klein K, Kumar A, Robinson J, Landucci G, Forthal DN, Montefiori DC, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, Michael NL, Kim JH, Soderberg KA, Giorgi EE, Blair L, Korber BT, Moog C, Shattock RJ, Letvin NL, Schmitz JE, Moody MA, Gao F, Ferrari G, Shaw GM, Haynes BF. PMID: 26237403; PMCID: PMC4523205.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansAnimalsCells
    61. Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein. PLoS One. 2015; 10(7):e0133509. Chukwuma VU, Hicar MD, Chen X, Nicholas KJ, Joyner A, Kalams SA, Landucci G, Forthal DN, Spearman PW, Crowe JE. PMID: 26226263; PMCID: PMC4520566.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    62. A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens. PLoS One. 2015; 10(5):e0125581. Dotsey EY, Gorlani A, Ingale S, Achenbach CJ, Forthal DN, Felgner PL, Gach JS. PMID: 25938510; PMCID: PMC4418728.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    63. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine. 2015 Apr 21; 33(17):2086-95. Sholukh AM, Watkins JD, Vyas HK, Gupta S, Lakhashe SK, Thorat S, Zhou M, Hemashettar G, Bachler BC, Forthal DN, Villinger F, Sattentau QJ, Weiss RA, Agatic G, Corti D, Lanzavecchia A, Heeney JL, Ruprecht RM. PMID: 25769884; PMCID: PMC4411954.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    64. Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM. Biochim Biophys Acta. 2015 Oct; 1854(10 Pt A):1536-44. Chromikova V, Mader A, Hofbauer S, Göbl C, Madl T, Gach JS, Bauernfried S, Furtmüller PG, Forthal DN, Mach L, Obinger C, Kunert R. PMID: 25748881; PMCID: PMC4582045.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    65. Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine. 2014 Nov 12; 32(48):6527-36. Lakhashe SK, Byrareddy SN, Zhou M, Bachler BC, Hemashettar G, Hu SL, Villinger F, Else JG, Stock S, Lee SJ, Vargas-Inchaustegui DA, Cofano EB, Robert-Guroff M, Johnson WE, Polonis VR, Forthal DN, Loret EP, Rasmussen RA, Ruprecht RM. PMID: 25245933; PMCID: PMC4343195.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCellsPHPublic Health
    66. Functions of Antibodies. Microbiol Spectr. 2014 Aug 15; 2(4):1-17. Forthal DN. PMID: 25215264; PMCID: PMC4159104.
      View in: PubMed   Mentions: 89     Fields:    
    67. Functions of Antibodies. Microbiol Spectr. 2014 Aug; 2(4):AID-0019-2014. Forthal DN. PMID: 26104200.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    68. Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits. Clin Vaccine Immunol. 2014 Aug; 21(8):1086-93. Venditto VJ, Wieczorek L, Molnar S, Teque F, Landucci G, Watson DS, Forthal D, Polonis VR, Levy JA, Szoka FC. PMID: 24872518; PMCID: PMC4135905.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    69. Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge. J Infect Dis. 2015 Jan 01; 211(1):45-52. Gupta S, Pegu P, Venzon DJ, Gach JS, Ma ZM, Landucci G, Miller CJ, Franchini G, Forthal DN. PMID: 24850790; PMCID: PMC4334821.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    70. Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology. 2014 Jan 20; 11:8. Sholukh AM, Byrareddy SN, Shanmuganathan V, Hemashettar G, Lakhashe SK, Rasmussen RA, Watkins JD, Vyas HK, Thorat S, Brandstoetter T, Mukhtar MM, Yoon JK, Novembre FJ, Villinger F, Landucci G, Forthal DN, Ratcliffe S, Tuero I, Robert-Guroff M, Polonis VR, Bilska M, Montefiori DC, Johnson WE, Ertl HC, Ruprecht RM. PMID: 24444350; PMCID: PMC3905655.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    71. HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One. 2014; 9(1):e85371. Gach JS, Achenbach CJ, Chromikova V, Berzins B, Lambert N, Landucci G, Forthal DN, Katlama C, Jung BH, Murphy RL. PMID: 24454852; PMCID: PMC3893210.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    72. The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog. 2013; 9(11):e1003776. Gupta S, Gach JS, Becerra JC, Phan TB, Pudney J, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ, Ping LH, Corti D, Moldt B, Hel Z, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ, Forthal DN. PMID: 24278022; PMCID: PMC3836734.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCellsCTClinical Trials
    73. New paradigms for functional HIV-specific nonneutralizing antibodies. Curr Opin HIV AIDS. 2013 Sep; 8(5):393-401. Forthal D, Hope TJ, Alter G. PMID: 23924999; PMCID: PMC4097845.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    74. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLoS One. 2013; 8(8):e72054. Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB. PMID: 23991039; PMCID: PMC3753353.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    75. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J Virol. 2013 Oct; 87(19):10447-59. Jaworski JP, Kobie J, Brower Z, Malherbe DC, Landucci G, Sutton WF, Guo B, Reed JS, Leon EJ, Engelmann F, Zheng B, Legasse A, Park B, Dickerson M, Lewis AD, Colgin LM, Axthelm M, Messaoudi I, Sacha JB, Burton DR, Forthal DN, Hessell AJ, Haigwood NL. PMID: 23885083; PMCID: PMC3807376.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    76. Antibody-dependent enhancement and the risk of HIV infection. Curr HIV Res. 2013 Jul; 11(5):421-6. Gorlani A, Forthal DN. PMID: 24191936.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    77. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS. 2013 Jun 01; 27(9):F13-20. Watkins JD, Sholukh AM, Mukhtar MM, Siddappa NB, Lakhashe SK, Kim M, Reinherz EL, Gupta S, Forthal DN, Sattentau QJ, Villinger F, Corti D, Ruprecht RM, CAVD Project Group. PMID: 23775002; PMCID: PMC4084966.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansAnimalsCells
    78. Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection. J Acquir Immune Defic Syndr. 2013 May 01; 63(1):31-3. Forthal DN, Landucci G, Chohan B, Richardson BA, McClelland RS, Jaoko W, Blish C, Overbaugh J. PMID: 23344546; PMCID: PMC3625514.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    79. Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLoS One. 2013; 8(3):e58724. Rosenberg Y, Sack M, Montefiori D, Forthal D, Mao L, Hernandez-Abanto S, Urban L, Landucci G, Fischer R, Jiang X. PMID: 23533588; PMCID: PMC3606348.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    80. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol. 2013 Mar; 87(6):3538-48. Vaccari M, Keele BF, Bosinger SE, Doster MN, Ma ZM, Pollara J, Hryniewicz A, Ferrari G, Guan Y, Forthal DN, Venzon D, Fenizia C, Morgan T, Montefiori D, Lifson JD, Miller CJ, Silvestri G, Rosati M, Felber BK, Pavlakis GN, Tartaglia J, Franchini G. PMID: 23325681; PMCID: PMC3592147.
      View in: PubMed   Mentions: 39     Fields:    Translation:AnimalsCells
    81. Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood. 2012 Oct 04; 120(14):2836-42. Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB. PMID: 22915639; PMCID: PMC3466964.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    82. In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds. Int J Antimicrob Agents. 2012 Oct; 40(4):354-60. Forthal DN, Phan TB, Slepenkin AV, Landucci G, Chu H, Elofsson M, Peterson E. PMID: 22819150; PMCID: PMC3438335.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    83. Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. Retrovirology. 2012 Jul 17; 9:57. Van Rompay KK, Trott KA, Jayashankar K, Geng Y, LaBranche CC, Johnson JA, Landucci G, Lipscomb J, Tarara RP, Canfield DR, Heneine W, Forthal DN, Montefiori D, Abel K. PMID: 22805180; PMCID: PMC3419085.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    84. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol. 2012 Jun; 86(11):6189-96. Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, Forthal DN, Schmitz JE, Iida S, Poignard P, Watkins DI, Hessell AJ, Burton DR. PMID: 22457527; PMCID: PMC3372207.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansAnimalsCells
    85. Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine. AIDS Res Hum Retroviruses. 2012 Sep; 28(9):1063-72. McBurney SP, Landucci G, Forthal DN, Ross TM. PMID: 22214267; PMCID: PMC3423648.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    86. High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. AIDS. 2012 Jan 14; 26(2):149-55. Rasmussen RA, Siddappa NB, Lakhashe SK, Watkins J, Villinger F, Ibegbu C, Florese RH, Robert-Guroff M, Montefiori DC, Forthal DN, O'Connor D, Ruprecht RM, Clade C Program Project Group. PMID: 21941166; PMCID: PMC3767758.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    87. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012 Jan 04; 482(7383):89-93. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL. PMID: 22217938; PMCID: PMC3271177.
      View in: PubMed   Mentions: 321     Fields:    Translation:AnimalsCells
    88. IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. AIDS. 2011 Nov 13; 25(17):2099-104. Forthal DN, Landucci G, Ding H, Kappes JC, Wang A, Thung I, Phan T. PMID: 21832933.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    89. Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine. 2011 Dec 09; 30(1):78-94. Bialuk I, Whitney S, Andresen V, Florese RH, Nacsa J, Cecchinato V, Valeri VW, Heraud JM, Gordon S, Parks RW, Montefiori DC, Venzon D, Demberg T, Guroff MR, Landucci G, Forthal DN, Franchini G. PMID: 22037204; PMCID: PMC3246802.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    90. Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol. 2010 Dec 01; 185(11):6876-82. Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H. PMID: 21041724.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansAnimalsCells
    91. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med. 2010 Oct; 16(10):1117-9. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal DN, Haigwood NL. PMID: 20890292; PMCID: PMC2952052.
      View in: PubMed   Mentions: 99     Fields:    Translation:AnimalsCells
    92. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med. 2010 Apr 12; 207(4):763-76. Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK, Kozink DM, Drinker MS, Zhang R, Xia SM, Sutherland LL, Tomaras GD, Giles IP, Kappes JC, Ochsenbauer-Jambor C, Edmonds TG, Soares M, Barbero G, Forthal DN, Landucci G, Chang C, King SW, Kavlie A, Denny TN, Hwang KK, Chen PP, Thorpe PE, Montefiori DC, Haynes BF. PMID: 20368576; PMCID: PMC2856026.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    93. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol. 2010 Feb; 84(3):1302-13. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, Burton DR. PMID: 19906907; PMCID: PMC2812338.
      View in: PubMed   Mentions: 209     Fields:    Translation:HumansCells
    94. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS. 2009 Sep; 4(5):388-93. Forthal DN, Moog C. PMID: 20048702; PMCID: PMC2882066.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansAnimalsCells
    95. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol. 2009 Sep; 83(18):9584-90. Barouch DH, Liu J, Lynch DM, O'Brien KL, La Porte A, Simmons NL, Riggs AM, Clark S, Abbink P, Montefiori DC, Landucci G, Forthal DN, Self SG, Carville A, Mansfield K, Goudsmit J. PMID: 19553307; PMCID: PMC2738237.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCellsPHPublic Health
    96. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009 May; 5(5):e1000433. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. PMID: 19436712; PMCID: PMC2674935.
      View in: PubMed   Mentions: 332     Fields:    Translation:HumansAnimalsCells
    97. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2009 Jan 01; 457(7225):87-91. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. PMID: 18997770; PMCID: PMC2614452.
      View in: PubMed   Mentions: 279     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    98. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008 Dec; 82(24):12449-63. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. PMID: 18842730; PMCID: PMC2593361.
      View in: PubMed   Mentions: 396     Fields:    Translation:HumansCells
    99. Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses. Virol J. 2008 Aug 04; 5:90. Eastman D, Piantadosi A, Wu X, Forthal DN, Landucci G, Kimata JT, Overbaugh J. PMID: 18680596; PMCID: PMC2518139.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    100. FcgammaRIIa genotype predicts progression of HIV infection. J Immunol. 2007 Dec 01; 179(11):7916-23. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. PMID: 18025239.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCells
    101. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007 Sep 06; 449(7158):101-4. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. PMID: 17805298.
      View in: PubMed   Mentions: 564     Fields:    Translation:HumansAnimalsCells
    102. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol. 2007 May 15; 178(10):6596-603. Forthal DN, Gilbert PB, Landucci G, Phan T. PMID: 17475891.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCells
    103. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol. 2007 May; 81(10):5024-35. Miller CJ, Genescà M, Abel K, Montefiori D, Forthal D, Bost K, Li J, Favre D, McCune JM. PMID: 17329327; PMCID: PMC1900210.
      View in: PubMed   Mentions: 42     Fields:    Translation:AnimalsCells
    104. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol. 2006 Sep 15; 177(6):4028-36. Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, Haigwood N, Venzon D, Kalyanaraman VS, Marthas ML, Robert-Guroff M. PMID: 16951366.
      View in: PubMed   Mentions: 44     Fields:    Translation:AnimalsCells
    105. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol. 2006 Sep; 80(18):9217-25. Forthal DN, Landucci G, Cole KS, Marthas M, Becerra JC, Van Rompay K. PMID: 16940533; PMCID: PMC1563916.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansAnimalsCells
    106. Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11. Virol J. 2006 Apr 03; 3:22. Van Rompay KK, Blackwood EJ, Landucci G, Forthal D, Marthas ML. PMID: 16584561; PMCID: PMC1500998.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    107. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS. 2005 Feb 18; 19(3):295-302. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, Forthal DN, Leedom J, Leibowitz M, McCutchan JA, Richman DD, California Collaborative Treatment Group. PMID: 15718840.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    108. Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol. 2005 Feb; 79(4):2042-9. Forthal DN, Landucci G, Phan TB, Becerra J. PMID: 15681406; PMCID: PMC546539.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    109. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005 Mar 01; 191(5):654-65. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp120 HIV Vaccine Study Group. PMID: 15688278.
      View in: PubMed   Mentions: 472     Fields:    Translation:HumansCellsCTClinical Trials
    110. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir Ther. 2004 Oct; 9(5):753-61. Yasuda JM, Miller C, Currier JS, Forthal DN, Kemper CA, Beall GN, Tilles JG, Capparelli EV, McCutchan JA, Haubrich RH, California Collaborative Treatment Group. PMID: 15535413.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    111. CD8+ T-cell mediated tumor protection by Pseudomonas exotoxin fused to ovalbumin in C57BL/6 mice. Surgery. 2003 Apr; 133(4):404-10. Becerra JC, Arthur JF, Landucci GR, Forthal DN, Theuer CP. PMID: 12717358.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    112. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002 Oct 18; 16(15):F33-40. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA, California Collaborative Treatment Group. PMID: 12370520.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsCTClinical Trials
    113. A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. Clin Infect Dis. 2001 Oct 01; 33(7):1060-8. Haubrich RH, Currier JS, Forthal DN, Beall G, Kemper CA, Johnson D, Dubé MP, Hwang J, Leedom JM, Tilles J, McCutchan JA, California Collaborative Treatment Group. PMID: 11528581.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    114. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol. 2001 Aug; 75(15):6953-61. Forthal DN, Landucci G, Daar ES. PMID: 11435575; PMCID: PMC114423.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCells
    115. Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts. Endocrinology. 2001 Jul; 142(7):2898-905. Reddy SV, Kurihara N, Menaa C, Landucci G, Forthal D, Koop BA, Windle JJ, Roodman GD. PMID: 11416009.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    116. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retroviruses. 2001 Apr 10; 17(6):553-61. Forthal DN, Landucci G, Keenan B. PMID: 11350669.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    117. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS. 2001 Mar 30; 15(5):609-15. Kemper CA, Witt MD, Keiser PH, Dubé MP, Forthal DN, Leibowitz M, Smith DS, Rigby A, Hellmann NS, Lie YS, Leedom J, Richman D, McCutchan JA, Haubrich R, California Collaborative Treatment Group #575 Team. PMID: 11316998.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    118. Antibody inhibition of cytomegalovirus: the role of natural killer and macrophage effector cells. Transpl Infect Dis. 2001; 3 Suppl 2:31-4. Forthal DN, Phan T, Landucci G. PMID: 11926747.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    119. Clinical isolates of measles virus use CD46 as a cellular receptor. J Virol. 2000 May; 74(9):3967-74. Manchester M, Eto DS, Valsamakis A, Liton PB, Fernandez-Muñoz R, Rota PA, Bellini WJ, Forthal DN, Oldstone MB. PMID: 10756008; PMCID: PMC111910.
      View in: PubMed   Mentions: 46     Fields:    Translation:AnimalsCells
    120. Sex-associated differences in the antibody-dependent cellular cytotoxicity antibody response to measles vaccines. Clin Diagn Lab Immunol. 2000 Jan; 7(1):111-3. Atabani S, Landucci G, Steward MW, Whittle H, Tilles JG, Forthal DN. PMID: 10618288; PMCID: PMC95833.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    121. Cytotoxic T lymphocyte precursors in persons with repeated exposure to human immunodeficiency virus. J Infect Dis. 1999 Oct; 180(4):1406-7. Forthal DN. PMID: 10479184.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    122. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis. 1999 Oct; 180(4):1338-41. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, Kaplan J. PMID: 10479168.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
    123. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. Lancet. 1999 Sep 11; 354(9182):891-5. Dunne MW, Bozzette S, McCutchan JA, Dubé MP, Sattler FR, Forthal D, Kemper CA, Havlir D. PMID: 10489947.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    124. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999 Jun 18; 13(9):1099-107. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, Dubé MP, Hwang JY, McCutchan JA. PMID: 10397541.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansCellsCTClinical Trials
    125. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis. 1998 Dec; 27(6):1369-75. Havlir DV, Dubé MP, McCutchan JA, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Kumar PN, White AC, Witt MD, Nightingale SD, Sepkowitz KA, MacGregor RR, Cheeseman SH, Torriani FJ, Zelasky MT, Sattler FR, Bozzette SA. PMID: 9868644.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    126. In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J Immunol Methods. 1998 Nov 01; 220(1-2):129-38. Forthal DN, Landucci G. PMID: 9839934.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    127. Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. California Collaborative Treatment Group. J Infect Dis. 1998 Mar; 177(3):595-9. Havlir DV, Haubrich R, Hwang J, Dunne MW, Currier J, Forthal D, Torriani F, Richman DD, McCutchan JA. PMID: 9498437.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    128. Lymphokine-activated cytotoxicity in peripheral blood mononuclear cells of severely immunocompromised HIV-infected patients. Scand J Immunol. 1997 Jan; 45(1):91-5. Forthal DN, Landucci G, Robinson WE. PMID: 9010505.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    129. Predominance of detrimental humoral immune responses to HIV-1 in AIDS patients with CD4 lymphocyte counts less than 400/mm3. Scand J Immunol. 1997 Jan; 45(1):103-11. McDougall B, Nymark MH, Landucci G, Forthal D, Robinson WE. PMID: 9010507.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    130. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996 Aug 08; 335(6):392-8. Havlir DV, Dubé MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White AC, Witt MD, Bozzette SA, McCutchan JA. PMID: 8676932.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCellsCTClinical Trials
    131. Age, sex, and household exposure are associated with the acute measles-specific antibody-dependent cellular cytotoxicity antibody response. J Infect Dis. 1995 Dec; 172(6):1587-91. Forthal DN, Landucci G, Habis A, Laxer M, Javato-Laxer M, Tilles JG, Janoff EN. PMID: 7594722.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    132. Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies. AIDS Res Hum Retroviruses. 1995 Sep; 11(9):1095-9. Forthal DN, Landucci G, Gorny MK, Zolla-Pazner S, Robinson WE. PMID: 8554906.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    133. The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group. Am J Med. 1995 Feb; 98(2):177-82. Bozzette SA, Forthal D, Sattler FR, Kemper C, Richman DD, Tilles JG, Leedom J, McCutchan JA. PMID: 7847434.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    134. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994 Oct; 19(4):741-5. Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, Bauer M, Tilles JG, McCutchan JA, Leedom JM. PMID: 7803641.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCTClinical Trials
    135. Comparison of the ProSpecT and Color Vue enzyme-linked immunoassays for the detection of Cryptosporidium in stool specimens. Diagn Microbiol Infect Dis. 1994 Aug; 19(4):221-5. Aarnaes SL, Blanding J, Speier S, Forthal D, de la Maza LM, Peterson EM. PMID: 7851085.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    136. Measles virus-specific functional antibody responses and viremia during acute measles. J Infect Dis. 1994 Jun; 169(6):1377-80. Forthal DN, Landucci G, Habis A, Zartarian M, Katz J, Tilles JG. PMID: 8195621.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    137. Comparison of measles virus-specific antibodies with antibody-dependent cellular cytotoxicity and neutralizing functions. J Infect Dis. 1993 Oct; 168(4):1020-3. Forthal DN, Landucci G, Katz J, Tilles JG. PMID: 8376813.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    138. Comparison of different methods and cell lines for isolating measles virus. J Clin Microbiol. 1993 Mar; 31(3):695-7. Forthal DN, Blanding J, Aarnaes S, Peterson EM, de la Maza LM, Tilles JG. PMID: 8458965; PMCID: PMC262845.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    139. Degree and length of viremia in adults with measles. J Infect Dis. 1992 Aug; 166(2):421-4. Forthal DN, Aarnaes S, Blanding J, de la Maza L, Tilles JG. PMID: 1634814.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    140. Inosine pranobex for preventing AIDS in patients with HIV infection. N Engl J Med. 1991 Feb 14; 324(7):491-2. Forthal DN. PMID: 1703281.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    141. The prevalence of infection with human immunodeficiency virus over a 10-year period in rural Zaire. N Engl J Med. 1988 Feb 04; 318(5):276-9. Nzilambi N, De Cock KM, Forthal DN, Francis H, Ryder RW, Malebe I, Getchell J, Laga M, Piot P, McCormick JB. PMID: 3336420.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    142. Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa. J Infect Dis. 1987 Nov; 156(5):833-7. Getchell JP, Hicks DR, Svinivasan A, Heath JL, York DA, Malonga M, Forthal DN, Mann JM, McCormick JB. PMID: 3309075.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    143. Treatment of bacterial meningitis with ceftazidime. Pediatr Infect Dis. 1986 Jul-Aug; 5(4):416-20. Hatch D, Overturf GD, Kovacs A, Forthal D, Leong C. PMID: 3523458.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    144. Danger on the Los Angeles freeway. N Engl J Med. 1984 Jul 26; 311(4):263. Forthal DN, Leong C, Overturf GD. PMID: 6738633.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    145. Disseminated coccidioidomycosis in a patient with acquired immune deficiency syndrome. West J Med. 1984 Mar; 140(3):447-9. Kovacs A, Forthal DN, Kovacs JA, Overturf GD. PMID: 6710985; PMCID: PMC1021715.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    146. Treatment of bacterial meningitis with ceftizoxime. Antimicrob Agents Chemother. 1984 Feb; 25(2):258-62. Overturf GD, Cable DC, Forthal DN, Shikuma C. PMID: 6324670; PMCID: PMC185485.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    147. Hypoalbuminemia after renal transplantation. Arch Surg. 1980 Mar; 115(3):286-9. Vaziri ND, Forthal D. PMID: 6986857.
      View in: PubMed   Mentions:    Fields:    Translation:Humans